Skip to content

Central Venous Access Device Removal in Cancer Patients

Frequency of Central Venous Port Catheter Removal Due to Suspected Infection in Patients Diagnosed With Cancer at a Single Institution: A Retrospective Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03855969
Enrollment
1402
Registered
2019-02-27
Start date
2019-03-01
Completion date
2019-12-30
Last updated
2020-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Malignancy, Oncology

Keywords

PAC infections, oncology

Brief summary

Background: Central venous catheters are frequently used during cancer treatment with the aim of venepreservation. It can facilitate venous access for the safe administration of irritating or vesicant intravenous cancer medications and / or other fluids, to collect blood samples or to ensure accurate venous access for contrast during medical imaging. In addition, this means more comfort for the patient who needs to be punctured less peripherally. However, central venous catheters can also be a source of bloodstream infections and other complications, leading to increased morbidity and hospital costs (1). In our hospital, there is a general practice that if an infection of the device is suspected, the central venous catheter should be removed if antibiotics do not seem or prove to be effective. The objective of this trial is to assess the frequency of implanted port catheter-removal in cancer patients due to suspected infection of the device in a particular oncology center over a time period of seven years. Furthermore, evidence for real device infections (per/post-surgery) and the potential contribution of different (institution-specific) risk factors on device infection will be explored. There will be focused on implanted port catheters only, as this is the main used central venous access device within the oncological population. Trial objectives: The primary aim of this retrospective descriptive trial is to evaluate the frequency of implanted port catheter-removal in cancer patients due to suspected infection of the device, over a time period of seven years. The secondary aim is to examine whether the device infection could be confirmed during or after removal of the device. At last, the tertiary aim is to verify whether certain variables can be denoted as potential risk factors for central venous access infection. Selection of those variables of interest will be based on a thorough review of the literature and discussion with the responsible healthcare professionals.

Interventions

PROCEDURERemoval of a central venous access device

We are interested in those patients for which a central venous access device was removed.

Sponsors

General Hospital Groeninge
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Central venous access device removal in our general hospital * Cancer patient

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Suspected infection rate2012-2017How many central venous access devices are removed due to a suspected infection of the device in cancer patients.

Secondary

MeasureTime frameDescription
Approved infection rate2012-2017For how many of the central venous access devices that were removed due to suspected infection of the device could an infection be confirmed?
Risk factors for central venous access device infections in cancer patients2012-2017Is it possible to denote certain variables as potential risk factors for central venous access device infection?

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026